Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa

Abstract

Liposomal formulations of two synergistic antibiotics was promising against multidrug resistant P. aeruginosa infections.

Polypeptide Self-Assembled Nanoparticles as Delivery Systems for Polymyxins B and E

“…This influence of protein present in the medium on the peptide release is already known. For instance, a faster release of polymyxin E from liposomes in diluted bovine serum in comparison with buffer solution has been reported elsewhere [ 25 ].…”

“…In general, the determined values for the EE are quite high in comparison with results published for other NPs. For example, the reported EE for polymyxin E into different liposomes ranged from 45% to 67% [ 24 , 25 , 47 ]. For polymeric carriers, an EE of 47% was reported for alginate/chitosan microparticles [ 31 , 32 ].…”

“…Besides the positive charge, the presence of a lipophilic tail, as well as the hydrophobic amino acids in the polymyxin peptide structure, allows the use of both amphiphilic and hydrophobic low-molecular compounds and polymers for drug delivery. Therefore, the delivery systems considered for polymyxins include anionic liposomes [ 22 , 23 , 24 , 25 ], lipid NPs [ 26 , 27 ], and different polymer systems [ 28 , 29 , 30 ]. The polymers include hydrophobic poly(butyl cyanoacrylate)-based NPs [ 29 ], poly( l -lactide)/halloysite nanotube nanofiber mats for wound treatment [ 30 ], and hybrid systems based on alginate-cross-linked polymyxin B loaded into lipid NPs [ 28 ].…”

Simultaneous Particle Size Reduction and Homogeneous Mixing to Produce Combinational Powder Formulations for Inhalation by the Single-Step Co-Jet Milling

“…Colistin and ciprofloxacin are selected as 2 model drugs here as these 2 antibiotics have shown synergistic antimicrobial activities against resistant Pseudomonas aeruginosa. 24,25 Colistin DPI (Colobreathe, in the form of colistimethate sodium) has been approved in the Europe, and ciprofloxacin DPI is under development. 26 Combining colistin and ciprofloxacin into a single DPI product may improve patients' compliance and maximize the antimicrobial activities.…”

Nanomedicines for Infectious Diseases

“…Given that drugs for infectious diseases are commonly administered as a cocktail of drugs, Wang et al developed a liposomal formulation for co-delivery of colistin and ciprofloxacin (9). Colistin delivery is important from the perspective that this drug is currently considered the last line of defence against multidrug resistant Pseudomonas infections.…”